Latest Abiraterone Stories
VANCOUVER, Canada and HOUSTON, TX, Feb. 27, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd.
HOUSTON, TX and VANCOUVER, Feb. 25, 2015 /PRNewswire/ - ESSA Pharma Inc.
Abstracts: 160, 182, 195, 202, 247, 253, 254 WHIPPANY, N.J., Feb. 23, 2015 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRES/ VANCOUVER, Jan. 27, 2015 /CNW/ - ESSA Pharma Inc.
VANCOUVER, Jan. 26, 2015 /PRNewswire/ - ESSA Pharma Inc.
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
The Majority of Surveyed Non-Prescribers Anticipate Prescribing Xofigo Within the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc.
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus
- A political dynamiter.